Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial

INTRODUCTION: We evaluated the clinical profile of the orexin receptor antagonist suvorexant for treating insomnia in patients with mild‐to‐moderate probable Alzheimer's disease (AD) dementia. METHODS: Randomized, double‐blind, 4‐week trial of suvorexant 10 mg (could be increased to 20 mg based...

Descripción completa

Detalles Bibliográficos
Autores principales: Herring, W. Joseph, Ceesay, Paulette, Snyder, Ellen, Bliwise, Donald, Budd, Kerry, Hutzelmann, Jill, Stevens, Joanne, Lines, Christopher, Michelson, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Featured Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984350/
https://www.ncbi.nlm.nih.gov/pubmed/31944580
http://dx.doi.org/10.1002/alz.12035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984350/
https://www.ncbi.nlm.nih.gov/pubmed/31944580
http://dx.doi.org/10.1002/alz.12035

Ejemplares similares